{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Controlled trials", "Interventions", "SARS-CoV-2", "Systematic review", "Treatment"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34762250", "DateCompleted": {"Year": "2021", "Month": "11", "Day": "29"}, "DateRevised": {"Year": "2024", "Month": "04", "Day": "04"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "11", "Day": "11"}], "Language": ["eng"], "ELocationID": ["10.1007/s40199-021-00422-8"], "Journal": {"ISSN": "2008-2231", "JournalIssue": {"Volume": "29", "Issue": "2", "PubDate": {"Year": "2021", "Month": "Dec"}}, "Title": "Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences", "ISOAbbreviation": "Daru"}, "ArticleTitle": "Characteristics of published/registered clinical trials on COVID-19 treatment: A systematic review.", "Pagination": {"StartPage": "449", "EndPage": "467", "MedlinePgn": "449-467"}, "Abstract": {"AbstractText": ["Due to the rapid spread of COVID-19 worldwide, many countries have designed clinical trials to find efficient\u00a0treatments. We aimed to critically report the characteristics of all the registered and published randomized clinical trials (RCTs) conducted on COVID-19, and summarize the evaluation of potential therapies developed in various regions.", "We comprehensively searched PubMed, Cochrane Library, Web of Science, Scopus, and Clinicaltrial.gov databases to retrieve all the relevant studies up to July 19, 2021, in conformity with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart. We included all English-language published/registered RCTs on COVID-19, and excluded non-RCT, in-vitro/in-vivo, editorials, and review studies. Two reviewers independently evaluated all the records, and then analyzed by using SPSS 17.", "Within 3018 included studies, 2801 (92.8%) and 217 (7.2%) were registered or published RCTs consisting of about 600 synthetic drugs. Herbal medicines have been studied in 23 trials (10.6%) among the published RCTs and in 357 registered RCTs (12.7%). Hydroxychloroquine 23 (10.6%) and convalescent plasma 194 (6.9%) alone or in combination with other agents were the most frequently used interventions in published and registered RCTs, respectively. Most published RCTs have been conducted in Western Pacific Region (WPRO) (50 trials, 23.0%) including 45 trials from China. Also, a greater proportion of registered RCTs have been conducted in the Region of the Americas (PAHO) (885 trials, 31.6%) including 596 RCTs from the United States (U.S). Globally, 283 registered trials have been conducted to assess new developed vaccines for COVID or previously established for other disorders.", "The present study highlighted the wide range of potential therapeutic agents in published and registered COVID-19 clinical trials across a wide range of regions. However, it is urgently required to global coordination in order to conduct more well-designed trials and progress in discovering safe and effective treatments."], "CopyrightInformation": "\u00a9 2021. Springer Nature Switzerland AG."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Asili", "ForeName": "Pooria", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Mirahmad", "ForeName": "Maryam", "Initials": "M"}, {"Identifier": ["0000-0003-0188-9721"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. tabatabaeiml@sina.tums.ac.ir."}], "LastName": "Tabatabaei-Malazy", "ForeName": "Ozra", "Initials": "O"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medicinal Plants Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Manayi", "ForeName": "Azadeh", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Haghighat", "ForeName": "Elahe", "Initials": "E"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Mahdavi", "ForeName": "Mohammad", "Initials": "M"}, {"Identifier": ["0000-0001-5386-7597"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Larijani", "ForeName": "Bagher", "Initials": "B"}], "PublicationTypeList": ["Journal Article", "Review", "Systematic Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Daru", "NlmUniqueID": "101125969", "ISSNLinking": "1560-8115"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Synthetic Drugs"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Clinical Trials as Topic"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["statistics & numerical data"], "DescriptorName": "Publications"}, {"QualifierName": ["classification", "therapeutic use"], "DescriptorName": "Synthetic Drugs"}, {"QualifierName": [], "DescriptorName": "Treatment Outcome"}, {"QualifierName": [], "DescriptorName": "COVID-19 Drug Treatment"}], "CoiStatement": "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Organization WH. Coronavirus disease (COVID-2019) situation reports: Geneva, Switzerland; 2021. Available from: https://covid19.who.int/. Accessed 30 Oct\u00a02021."}, {"Citation": "Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ. 2020;371:m3862. doi: 10.1136/bmj.m3862.", "ArticleIdList": ["10.1136/bmj.m3862", "33097561"]}, {"Citation": "Organization WH. WHO Coronavirus Disease (COVID-19) Dashboard: Geneva, Switzerland; 2021. Available from: https://covid19.who.int/. Accessed 30 Oct\u00a02021."}, {"Citation": "Chahrour M, Assi S, Bejjani M, Nasrallah AA, Salhab H, Fares M, et al. A bibliometric analysis of COVID-19 research activity: a call for increased output. Cureus. 2020;12(3):e7357-e. doi: 10.7759/cureus.7357.", "ArticleIdList": ["10.7759/cureus.7357", "PMC7174863", "32328369"]}, {"Citation": "Atlasi R, Noroozi Chakoli A, Ramezani A, Tabatabaei-Malazy O, Larijani B. Scientometric analyzing the output of researchers and organizations on COVID-19 for better conducting the scientific efforts: with a glance to endocrinology. J Diabetes Metab Disord. 2021;20(1):1\u201312. doi: 10.1007/s40200-020-00718-7.", "ArticleIdList": ["10.1007/s40200-020-00718-7", "PMC7843242", "33532371"]}, {"Citation": "Cheng VC, Chan JF, To KK, Yuen K. Clinical management and infection control of SARS: lessons learned. Antiviral Res. 2013;100(2):407\u2013419. doi: 10.1016/j.antiviral.2013.08.016.", "ArticleIdList": ["10.1016/j.antiviral.2013.08.016", "PMC7132413", "23994190"]}, {"Citation": "Yousefifard M, Zali A, Mohamed Ali K, Madani Neishaboori A, Zarghi A, Hosseini M, et al. Antiviral therapy in management of COVID-19: a systematic review on current evidence. Arch Acad Emerg Med. 2020;8(1):e45-e. doi: 10.22037/aaem.v8i1.658.", "ArticleIdList": ["10.22037/aaem.v8i1.658", "PMC7156260", "32309809"]}, {"Citation": "Mehta HB, Ehrhardt S, Moore TJ, Segal JB, Alexander GC. Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis. BMJ Open. 2020;10(6):e039978. doi: 10.1136/bmjopen-2020-039978.", "ArticleIdList": ["10.1136/bmjopen-2020-039978", "PMC7286283", "32518212"]}, {"Citation": "Rabby MII, Hossain F. Study of ongoing registered clinical trials on COVID-19: a narrative review. Sao Paulo Med J. 2020;138:441\u201356. doi: 10.1590/1516-3180.2020.0208.r1.15062020.", "ArticleIdList": ["10.1590/1516-3180.2020.0208.r1.15062020", "PMC9673863", "32813843"]}, {"Citation": "Wang Y, Zhou Q, Xu M, Kang J, Chen Y. Characteristics of clinical trials relating to COVID-19 registered at ClinicalTrials.gov. J Clin Pharm Ther. 2020;45(6):1357\u201362. doi: 10.1111/jcpt.13222.", "ArticleIdList": ["10.1111/jcpt.13222", "32734670"]}, {"Citation": "Aslam A, Imanullah S, Asim M, El-Menyar A. Registration of clinical trials: Is it really needed? N Am J Med Sci. 2013;5(12):713. doi: 10.4103/1947-2714.123266.", "ArticleIdList": ["10.4103/1947-2714.123266", "PMC3877534", "24404555"]}, {"Citation": "Xie J, Wang Z, Liang J, Lin H, Yang Z, Wang Y, et al. Critical review of the scientific evidence and recommendations in COVID-19 management guidelines. Open Forum Infect Dis. 2021;8(8):ofab376. doi: 10.1093/ofid/ofab376.", "ArticleIdList": ["10.1093/ofid/ofab376", "PMC8360242", "34395712"]}, {"Citation": "Casadevall A, Pirofski L-A. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130(4):1545\u20131548. doi: 10.1172/JCI138003.", "ArticleIdList": ["10.1172/JCI138003", "PMC7108922", "32167489"]}, {"Citation": "The RCG, Horby PW, Estcourt L, Peto L, Emberson JR, Staplin N, et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv. 2021:2021.03.09.21252736; 10.1101/2021.03.09.21252736"}, {"Citation": "Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, V\u00e1zquez C, et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med. 2020;384(7):619\u2013629. doi: 10.1056/NEJMoa2031304.", "ArticleIdList": ["10.1056/NEJMoa2031304", "PMC7722692", "33232588"]}, {"Citation": "O\u2019Donnell MR, Grinsztejn B, Cummings MJ, Justman J, Lamb MR, Eckhardt CM, et al. A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19. medRxiv. 2021:2021.03.12.21253373; 10.1101/2021.03.12.21253373", "ArticleIdList": ["PMC8245169", "33974559"]}, {"Citation": "Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) BMJ. 2020;371:m3939. doi: 10.1136/bmj.m3939.", "ArticleIdList": ["10.1136/bmj.m3939", "PMC7578662", "33093056"]}, {"Citation": "Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324(5):460\u2013470. doi: 10.1001/jama.2020.10044.", "ArticleIdList": ["10.1001/jama.2020.10044", "PMC7270883", "32492084"]}, {"Citation": "FDA. Recommendations for investigational COVID-19 convalescent plasma: Food and Drug Administration; 2020 .Available from: https://www.fda.gov/media/141477/download. Accessed 30 Aug 2021."}, {"Citation": "Sarkar C, Mondal M, Torequl Islam M, Martorell M, Docea AO, Maroyi A, et al. Potential therapeutic options for COVID-19: current status, challenges, and future perspectives. Front Pharmacol. 2020;11(1428):1239. doi: 10.3389/fphar.2020.572870.", "ArticleIdList": ["10.3389/fphar.2020.572870", "PMC7522523", "33041814"]}, {"Citation": "Chen J, Xia L, Liu L, Xu Q, Ling Y, Huang D, et al. Antiviral activity and safety of darunavir/cobicistat for the treatment of COVID-19. Open Forum Infect Dis. 2020;7(7):ofaa241. doi: 10.1093/ofid/ofaa241.", "ArticleIdList": ["10.1093/ofid/ofaa241", "PMC7337805", "32671131"]}, {"Citation": "Vicenti I, Zazzi M, Saladini F. SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. Expert Opin Ther Pat. 2021;31(4):325\u2013337. doi: 10.1080/13543776.2021.1880568.", "ArticleIdList": ["10.1080/13543776.2021.1880568", "PMC7938656", "33475441"]}, {"Citation": "Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 \u2014 final report. N Engl J Med. 2020;383(19):1813\u20131826. doi: 10.1056/NEJMoa2007764.", "ArticleIdList": ["10.1056/NEJMoa2007764", "PMC7262788", "32445440"]}, {"Citation": "Consortium WST Repurposed antiviral drugs for COVID-19\u2014interim WHO SOLIDARITY trial results. N Engl J Med. 2021;384:497\u2013511. doi: 10.1056/NEJMoa2023184.", "ArticleIdList": ["10.1056/NEJMoa2023184", "PMC7727327", "33264556"]}, {"Citation": "Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10238):1569\u20131578. doi: 10.1016/S0140-6736(20)31022-9.", "ArticleIdList": ["10.1016/S0140-6736(20)31022-9", "PMC7190303", "32423584"]}, {"Citation": "Mahajan L, Singh AP, Gifty Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: a prospective randomised study. Indian J Anaesth. 2021;65(Suppl 1):S41-s6. doi: 10.4103/ija.IJA_149_21.", "ArticleIdList": ["10.4103/ija.IJA_149_21", "PMC7993042", "33814589"]}, {"Citation": "FDA. Fact sheet for health care providers: Emergency Use Authorization (EUA) of remdesivir: Food and Drug Administration; 2021. Available from: https://www.fda.gov/media/137566/download. Accessed 30 Aug 2021."}, {"Citation": "Khalili H, Nourian A, Ahmadinejad Z, Emadi Kouchak H, Jafari S, Dehghan Manshadi SA, et al. Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial. Acta Biomed. 2020;91(4):e2020102. doi: 10.23750/abm.v91i4.10877.", "ArticleIdList": ["10.23750/abm.v91i4.10877", "PMC7927527", "33525212"]}, {"Citation": "Sadeghi A, Ali Asgari A, Norouzi A, Kheiri Z, Anushirvani A, Montazeri M, et al. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. J Antimicrob Chemother. 2020;75(11):3379\u20133385. doi: 10.1093/jac/dkaa334.", "ArticleIdList": ["10.1093/jac/dkaa334", "PMC7454592", "32812039"]}, {"Citation": "Abbaspour Kasgari H, Moradi S, Shabani AM, Babamahmoodi F, Davoudi Badabi AR, Davoudi L, et al. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial. J Antimicrob Chemother. 2020;75(11):3373\u20133378. doi: 10.1093/jac/dkaa332.", "ArticleIdList": ["10.1093/jac/dkaa332", "PMC7454669", "32812025"]}, {"Citation": "Roozbeh F, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Merat S, Wentzel H, et al. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. J Antimicrob Chemother. 2021;76(3):753\u2013757. doi: 10.1093/jac/dkaa501.", "ArticleIdList": ["10.1093/jac/dkaa501", "PMC7798988", "33338232"]}, {"Citation": "Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;382(25):2411\u20132418. doi: 10.1056/NEJMoa2012410.", "ArticleIdList": ["10.1056/NEJMoa2012410", "PMC7224609", "32379955"]}, {"Citation": "Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for Coronavirus Disease 2019 (COVID-19) JAMA Cardiol. 2020;5(9):1036\u20131041. doi: 10.1001/jamacardio.2020.1834.", "ArticleIdList": ["10.1001/jamacardio.2020.1834", "PMC7195692", "32936252"]}, {"Citation": "Nguyen LS, Dolladille C, Drici M-D, Fenioux C, Alexandre J, Mira J-P, et al. Cardiovascular toxicities associated with hydroxychloroquine and azithromycin: an analysis of the World Health Organization Pharmacovigilance Database. Circulation. 2020;142(3):303\u2013305. doi: 10.1161/CIRCULATIONAHA.120.048238.", "ArticleIdList": ["10.1161/CIRCULATIONAHA.120.048238", "PMC7365677", "32442023"]}, {"Citation": "FDA. Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine: Food and Drug Administration; 2020. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and. Accessed 30 Aug 2021."}, {"Citation": "Borcherding N, Jethava Y, Vikas P. Repurposing anti-cancer drugs for COVID-19 treatment. Drug Des Dev Ther. 2020;14:5045. doi: 10.2147/DDDT.S282252.", "ArticleIdList": ["10.2147/DDDT.S282252", "PMC7680713", "33239864"]}, {"Citation": "Saini KS, Lanza C, Romano M, de Azambuja E, Cortes J, de Las HB, et al. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy. Br J Cancer. 2020;123(5):694\u2013697. doi: 10.1038/s41416-020-0948-x.", "ArticleIdList": ["10.1038/s41416-020-0948-x", "PMC7307309", "32572174"]}, {"Citation": "Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodr\u00edguez L. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62\u201375. doi: 10.1016/j.cytogfr.2020.06.001.", "ArticleIdList": ["10.1016/j.cytogfr.2020.06.001", "PMC7265853", "32513566"]}, {"Citation": "Yousefi H, Mashouri L, Okpechi SC, Alahari N, Alahari SK. Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: a review describing drug mechanisms of action. Biochem Pharmacol. 2021;183:114296. doi: 10.1016/j.bcp.2020.114296.", "ArticleIdList": ["10.1016/j.bcp.2020.114296", "PMC7581400", "33191206"]}, {"Citation": "El-Goly AMM. Lines of treatment of COVID-19 Infection. Covid-19 infections and pregnancy. 2021;p. 91\u2013144; 10.1016/B978-0-323-90595-4.00002-9"}, {"Citation": "Gendrot M, Duflot I, Boxberger M, Delandre O, Jardot P, Le Bideau M, et al. Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: in vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate. Int J Infect Dis. 2020;99:437\u2013440. doi: 10.1016/j.ijid.2020.08.032.", "ArticleIdList": ["10.1016/j.ijid.2020.08.032", "PMC7426697", "32805422"]}, {"Citation": "Group TWREAfC-TW. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330\u201341; 10.1001/jama.2020.17023", "ArticleIdList": ["PMC7489434", "32876694"]}, {"Citation": "Organization WH. Corticosteroids for COVID-19: living guidance, 2 September 2020: Geneva, Switzerland; 2020 [Available from: https://apps.who.int/iris/handle/10665/334125] Accessed 30 Aug 2021."}, {"Citation": "Lam S, Lombardi A, Ouanounou A. COVID-19: A review of the proposed pharmacological treatments. Eur J Pharmacol. 2020;886:173451. doi: 10.1016/j.ejphar.2020.173451.", "ArticleIdList": ["10.1016/j.ejphar.2020.173451", "PMC7406477", "32768505"]}, {"Citation": "Abbasifard M, Khorramdelazad H. The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics. Life Sci. 2020;257:118097. doi: 10.1016/j.lfs.2020.118097.", "ArticleIdList": ["10.1016/j.lfs.2020.118097", "PMC7361088", "32679148"]}, {"Citation": "FDA. Fact sheet for health care providers Emergency Use Authorization (EUA) of Bamlanivimab: Food and Drug Administration; 2021 [Available from: https://www.fda.gov/media/143603/download] Accessed 30 Aug 2021."}, {"Citation": "Group RC Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637\u20131645. doi: 10.1016/S0140-6736(21)00676-0.", "ArticleIdList": ["10.1016/S0140-6736(21)00676-0", "PMC8084355", "33933206"]}, {"Citation": "Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021;384(1):20\u201330. doi: 10.1056/NEJMoa2030340.", "ArticleIdList": ["10.1056/NEJMoa2030340", "PMC7781101", "33332779"]}, {"Citation": "Investigators R-C, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384(16):1491\u20131502. doi: 10.1056/NEJMoa2100433.", "ArticleIdList": ["10.1056/NEJMoa2100433", "PMC7953461", "33631065"]}, {"Citation": "Rosas IO, Br\u00e4u N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021;384(16):1503\u20131516. doi: 10.1056/NEJMoa2028700.", "ArticleIdList": ["10.1056/NEJMoa2028700", "PMC7953459", "33631066"]}, {"Citation": "Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, et al. Effect of Tocilizumab vs Standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):24\u201331. doi: 10.1001/jamainternmed.2020.6615.", "ArticleIdList": ["10.1001/jamainternmed.2020.6615", "PMC7577199", "33080005"]}, {"Citation": "Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383(24):2333\u20132344. doi: 10.1056/NEJMoa2028836.", "ArticleIdList": ["10.1056/NEJMoa2028836", "PMC7646626", "33085857"]}, {"Citation": "Hermine O, Mariette X, Tharaux P-L, Resche-Rigon M, Porcher R, Ravaud P, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):32\u201340. doi: 10.1001/jamainternmed.2020.6820.", "ArticleIdList": ["10.1001/jamainternmed.2020.6820", "PMC7577198", "33080017"]}, {"Citation": "Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2021;384(3):229\u2013237. doi: 10.1056/NEJMoa2029849.", "ArticleIdList": ["10.1056/NEJMoa2029849", "PMC7646625", "33113295"]}, {"Citation": "Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384(3):238\u2013251. doi: 10.1056/NEJMoa2035002.", "ArticleIdList": ["10.1056/NEJMoa2035002", "PMC7781102", "33332778"]}, {"Citation": "Wolf J, Abzug MJ, Wattier RL, Sue PK, Vora SB, Zachariah P, et al. Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of COVID-19 in Children and Adolescents. J Pediatric Infect Dis Soc. 2021:629\u201334. 10.1093/jpids/piaa175", "ArticleIdList": ["PMC7799019", "33388760"]}, {"Citation": "Meffre E, Iwasaki A. Interferon deficiency can lead to severe COVID. Nature. 2020;587(7834):374\u2013376. doi: 10.1038/d41586-020-03070-1.", "ArticleIdList": ["10.1038/d41586-020-03070-1", "33139913"]}, {"Citation": "Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011;472(7344):481\u2013485. doi: 10.1038/nature09907.", "ArticleIdList": ["10.1038/nature09907", "PMC3409588", "21478870"]}, {"Citation": "Rahmani H, Davoudi-Monfared E, Nourian A, Khalili H, Hajizadeh N, Jalalabadi NZ, et al. Interferon \u03b2-1b in treatment of severe COVID-19: A randomized clinical trial. Int Immunopharmacol. 2020;88:106903. doi: 10.1016/j.intimp.2020.106903.", "ArticleIdList": ["10.1016/j.intimp.2020.106903", "PMC7445008", "32862111"]}, {"Citation": "Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, et al. A randomized clinical trial of the efficacy and safety of Interferon \u03b2-1a in treatment of severe COVID-19. Antimicrob Agents Chemother. 2020;64(9):e01061\u2013e1120. doi: 10.1128/AAC.01061-20.", "ArticleIdList": ["10.1128/AAC.01061-20", "PMC7449227", "32661006"]}, {"Citation": "Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(2):196\u2013206. doi: 10.1016/S2213-2600(20)30511-7.", "ArticleIdList": ["10.1016/S2213-2600(20)30511-7", "PMC7836724", "33189161"]}, {"Citation": "Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787. doi: 10.1016/j.antiviral.2020.104787.", "ArticleIdList": ["10.1016/j.antiviral.2020.104787", "PMC7129059", "32251768"]}, {"Citation": "L\u00f3pez-Medina E, L\u00f3pez P, Hurtado IC, D\u00e1valos DM, Ramirez O, Mart\u00ednez E, et al. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. JAMA. 2021;325(14):1426\u20131435. doi: 10.1001/jama.2021.3071.", "ArticleIdList": ["10.1001/jama.2021.3071", "PMC7934083", "33662102"]}, {"Citation": "Chachar AZK, Khan KA, Asif M, Tanveer K, Khaqan A, Basri R. Effectiveness of ivermectin in SARS-CoV-2/COVID-19 patients. Int J Sci. 2020;9(09):31\u20135. doi: 10.18483/ijSci.2378.", "ArticleIdList": ["10.18483/ijSci.2378"]}, {"Citation": "Chowdhury ATMM, Shahbaz M, Karim MR, Islam J, Guo D, He S. A randomized trial of ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID19 patients. Research Square. 2021. 10.21203/rs.3.rs-38896/v1"}, {"Citation": "Hashim HA, Maulood MF, Rasheed AM, Fatak DF, Kabah KK, Abdulamir AS. Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq. medRxiv. 2020:2020.10.26.20219345; 10.1101/2020.10.26.20219345"}, {"Citation": "Morteza Shakhsi N, Nematollah G, Peyman N, Abbas A, Leila Z, Amir J, et al. Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: a randomized multi-center clinical trial. Research Square. 2021.\u00a010.21203/rs.3.rs-109670/v1"}, {"Citation": "Okumu\u015f N, Demirt\u00fcrk N, \u00c7etinkaya RA, G\u00fcner R, Avc\u0131 \u0130Y, Orhan S, et al. Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. BMC Infect Dis. 2021;21(1):411. doi: 10.1186/s12879-021-06104-9.", "ArticleIdList": ["10.1186/s12879-021-06104-9", "PMC8093585", "33947344"]}, {"Citation": "Aref ZF, Bazeed S, Hassan MH, Hassan AS, Rashad A, Hassan RG, et al. Clinical, biochemical and molecular evaluations of ivermectin mucoadhesive nanosuspension nasal spray in reducing upper respiratory symptoms of mild COVID-19. Int J Nanomed. 2021;16:4063\u20134072. doi: 10.2147/ijn.s313093.", "ArticleIdList": ["10.2147/ijn.s313093", "PMC8215847", "34163159"]}, {"Citation": "Abd-Elsalam S, Noor RA, Badawi R, Khalaf M, Esmail ES, Soliman S, et al. Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: a randomized controlled study. J Med Virol. 2021;93(10):5833\u20135838. doi: 10.1002/jmv.27122.", "ArticleIdList": ["10.1002/jmv.27122", "PMC8242425", "34076901"]}, {"Citation": "Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021;103:214\u2013216. doi: 10.1016/j.ijid.2020.11.191.", "ArticleIdList": ["10.1016/j.ijid.2020.11.191", "PMC7709596", "33278625"]}, {"Citation": "Becker RC. COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis. 2020;50(1):54\u201367. doi: 10.1007/s11239-020-02134-3.", "ArticleIdList": ["10.1007/s11239-020-02134-3", "PMC7225095", "32415579"]}, {"Citation": "Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033\u20132040. doi: 10.1182/blood.2020006000.", "ArticleIdList": ["10.1182/blood.2020006000", "PMC7273827", "32339221"]}, {"Citation": "Nadkarni GN, Lala A, Bagiella E, Chang HL, Moreno PR, Pujadas E, et al. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. J Am Coll Cardiol. 2020;76(16):1815\u20131826. doi: 10.1016/j.jacc.2020.08.041.", "ArticleIdList": ["10.1016/j.jacc.2020.08.041", "PMC7449655", "32860872"]}, {"Citation": "Lopes RD, de Barros ESPGM, Furtado RHM, Macedo AVS, Bronhara B, Damiani LP, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet. 2021;397(10291):2253\u201363. doi: 10.1016/s0140-6736(21)01203-4.", "ArticleIdList": ["10.1016/s0140-6736(21)01203-4", "PMC8177770", "34097856"]}, {"Citation": "Tabatabaei-Malazy O, Abdollahi M, Larijani B. Beneficial effects of anti-oxidative herbal medicines in diabetic patients infected with COVID-19: a hypothesis. Diabetes Metab Syndr Obes. 2020;13:3113\u20133116. doi: 10.2147/DMSO.S264824.", "ArticleIdList": ["10.2147/DMSO.S264824", "PMC7467661", "32943897"]}, {"Citation": "Ang L, Song E, Lee HW, Lee MS. Herbal medicine for the treatment of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis of randomized controlled trials. J Clin Med. 2020;9(5):1583. doi: 10.3390/jcm9051583.", "ArticleIdList": ["10.3390/jcm9051583", "PMC7290825", "32456123"]}, {"Citation": "Murck H. Symptomatic protective action of glycyrrhizin (licorice) in COVID-19 infection? Front Immunol. 2020;11:1239. doi: 10.3389/fimmu.2020.01239.", "ArticleIdList": ["10.3389/fimmu.2020.01239", "PMC7270278", "32574273"]}, {"Citation": "Safa O, Hassani-Azad M, Farashahinejad M, Davoodian P, Dadvand H, Hassanipour S, et al. Effects of Licorice on clinical symptoms and laboratory signs in moderately ill patients with pneumonia from COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials. 2020;21(1):1\u20133. doi: 10.1186/s13063-020-04706-3.", "ArticleIdList": ["10.1186/s13063-020-04706-3", "PMC7490778", "32933552"]}, {"Citation": "Gomaa AA, Abdel-Wadood YA. The potential of glycyrrhizin and licorice extract in combating COVID-19 and associated conditions. Phytomedicine Plus. 2021:100043. 10.1016/j.phyplu.2021.100043", "ArticleIdList": ["PMC7886629", "35399823"]}, {"Citation": "Bouchentouf S, Missoum N. Identification of Compounds from Nigella Sativa as New Potential Inhibitors of 2019 Novel Coronasvirus (Covid-19): Molecular Docking Study. Preprints. 2020. 10.26434/chemrxiv.12055716.v1"}, {"Citation": "Pawar KS, Mastud RN, Pawar SK, Pawar SS, Bhoite RR, Bhoite RR, et al. Oral curcumin with piperine as adjuvant therapy for the treatment of COVID-19: a randomized clinical trial. Front Pharmacol. 2021;12:7. doi: 10.3389/fphar.2021.669362.", "ArticleIdList": ["10.3389/fphar.2021.669362", "PMC8193734", "34122090"]}, {"Citation": "Di Pierro F, Derosa G, Maffioli P, Bertuccioli A, Togni S, Riva A, Allegrini P, Khan A, Khan S, Khan BA, Altaf N, Zahid M, Din Ujjan I, Nigar R, Khushk MI, Phulpoto M, Lail A, Devrajani BR, Ahmed S. Possible therapeutic effects of adjuvant quercetin supplementation against early-stage COVID-19 infection: a prospective, randomized, controlled, and open-label study. Int J Gen Med. 2021;14:2359\u201366. doi: 10.2147/IJGM.S318720.", "ArticleIdList": ["10.2147/IJGM.S318720", "PMC8197660", "34135619"]}, {"Citation": "Di Pierro F, Iqtadar S, Khan A, Mumtaz SU, Chaudhry MM, Bertuccioli A, Derosa G, Maffioli P, Togni S, Riva A, Allegrini P, Khan S. Potential clinical benefits of quercetin in the early stage of COVID-19: results of a second, pilot, randomized, controlled and open-label clinical trial. Int J Gen Med. 2021;14:2807\u201316. doi: 10.2147/IJGM.S318949.", "ArticleIdList": ["10.2147/IJGM.S318949", "PMC8238537", "34194240"]}, {"Citation": "Hu K, Guan WJ, Bi Y, Zhang W, Li LJ, Zhang BL, et al. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial. Phytomedicine. 2021;85:9. doi: 10.1016/j.phymed.2020.153242.", "ArticleIdList": ["10.1016/j.phymed.2020.153242", "PMC7229744", "33867046"]}, {"Citation": "Xiao M, Tian J, Zhou Y, Xu X, Min X, Lv Y, et al. Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: a randomized controlled trial. Pharmacol Res. 2020;161:105126. doi: 10.1016/j.phrs.2020.105126.", "ArticleIdList": ["10.1016/j.phrs.2020.105126", "PMC7414728", "32781283"]}, {"Citation": "Xu X, Zhang J, Zheng W, Yang Z, Zhao X, Wang C, et al. Efficacy and safety of Reduning injection in the treatment of COVID-19: a randomized, multicenter clinical study. Ann Palliat Med. 2021;10(5):5146\u201355. doi: 10.21037/apm-20-2121.", "ArticleIdList": ["10.21037/apm-20-2121", "33894725"]}, {"Citation": "Luo ZJ, Chen W, Xiang MQ, Wang H, Xiao W, Xu C, et al. The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: a prospective randomized controlled trial. Eur J Integr Med. 2021;42:8. doi: 10.1016/j.eujim.2021.101305.", "ArticleIdList": ["10.1016/j.eujim.2021.101305", "PMC7847185", "33552315"]}, {"Citation": "Mesri M, Esmaeili Saber SS, Godazi M, Roustaei Shirdel A, Montazer R, Koohestani HR, et al. The effects of combination of Zingiber officinale and Echinacea on alleviation of clinical symptoms and hospitalization rate of suspected COVID-19 outpatients: a randomized controlled trial. J Complement Integr Med. 2021 doi: 10.1515/jcim-2020-0283.", "ArticleIdList": ["10.1515/jcim-2020-0283", "33787192"]}, {"Citation": "Sardari S, Mobaien A, Ghassemifard L, Kamali K, Khavasi N. Therapeutic effect of thyme (Thymus vulgaris) essential oil on patients with covid19: a randomized clinical trial. J Adv Med Biomed Res. 2021;29(133):83\u201391. doi: 10.30699/jambs.29.133.83.", "ArticleIdList": ["10.30699/jambs.29.133.83"]}, {"Citation": "Kumar A, Meldgaard TS, Bertholet S. Novel platforms for the development of a Universal Influenza Vaccine. Front Immunol. 2018;9:600. doi: 10.3389/fimmu.2018.00600.", "ArticleIdList": ["10.3389/fimmu.2018.00600", "PMC5877485", "29628926"]}, {"Citation": "Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;20(10):615\u2013632. doi: 10.1038/s41577-020-00434-6.", "ArticleIdList": ["10.1038/s41577-020-00434-6", "PMC7472682", "32887954"]}, {"Citation": "Wang J, Peng Y, Xu H, Cui Z, Williams RO. The COVID-19 vaccine race: challenges and opportunities in vaccine formulation. AAPS PharmSciTech. 2020;21(6):225. doi: 10.1208/s12249-020-01744-7.", "ArticleIdList": ["10.1208/s12249-020-01744-7", "PMC7405756", "32761294"]}, {"Citation": "Kyriakidis NC, L\u00f3pez-Cort\u00e9s A, Gonz\u00e1lez EV, Grimaldos AB, Prado EO. 2021. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. npj Vaccines. 6(1):28. 10.1038/s41541-021-00292-w", "ArticleIdList": ["PMC7900244", "33619260"]}, {"Citation": "Organization WH. WHO Director-General\u2019s opening remarks at the media briefing on COVID-19\u201311 March 2020: Geneva, Switzerland; 2020 [Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---18-march-2020. Accessed 30 Oct\u00a02021."}, {"Citation": "Cattani M. Global coalition to accelerate COVID-19 clinical research in resource-limited settings. Lancet. 2020;395(10233):P1322\u2013P1325. doi: 10.1016/S0140-6736(20)30798-4.", "ArticleIdList": ["10.1016/S0140-6736(20)30798-4", "PMC7270833", "32247324"]}, {"Citation": "Hasford J. Impact of the COVID-19 pandemic on clinical trials with drugs. Expert Opin Drug Saf. 2020;19(11):1373\u20131375. doi: 10.1080/14740338.2020.1828861.", "ArticleIdList": ["10.1080/14740338.2020.1828861", "32970481"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "4", "Day": "26"}, {"Year": "2021", "Month": "10", "Day": "13"}, {"Year": "2021", "Month": "11", "Day": "12", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "11", "Day": "30", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "11", "Day": "11", "Hour": "12", "Minute": "29"}, {"Year": "2022", "Month": "11", "Day": "11"}], "PublicationStatus": "ppublish", "ArticleIdList": ["34762250", "PMC8581284", "10.1007/s40199-021-00422-8", "10.1007/s40199-021-00422-8"]}}], "PubmedBookArticle": []}